Grünenthal, a science-based pharmaceutical company developing treatments for different pain conditions, announced that its U.S. subsidiary Averitas Pharma received U.S. Food and Drug Administration (FDA) approval for QUTENZA® (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults.
QUTENZA® is a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch and is the first and only treatment of its kind to deliver prescription strength capsaicin directly into the skin. Thereby, it can reversibly desensitize the TRPV1 receptor, which plays a critical role in pain signaling, and provide sustained relief that lasts for up to three months.
QUTENZA® 8% patch has been approved in the US for the management of neuropathic pain associated with postherpetic neuralgia since 2009.
Read the full press release here.
Read more about Grünenthal here.
Read more about Averitas Pharma here.
Photo by Elle Hughes on Unsplash